Wound Healing Process as the Most Appropriate Modality of Cancer Therapy
DOI:
https://doi.org/10.14738/aivp.111.13904Abstract
President Biden of USA declared cancer moonshot initiative on Sept. 12, 2022 to urge the health profession to come up solutions to save 50% of cancer patients in the following 25 years. Cancer therapies were dominated by strategy based on killing of cancer cells in the past, which have been drilled through as a presidential project, but failed to achieve the goal to win the war on cancer. Obviously, a drastic change of strategy is necessary to fulfill moonshot of President Biden. Wound healing requires the proliferation and the terminal differentiation of progenitor stem cells (PSCs). Wound healing comes naturally, because the nature creates chemo-surveillance to ensure perfection of wound healing. Healthy people are able to maintain a steady level of wound heading metabolites active as differentiation inducers (DIs) and differentiation helper inducers (DHIs) to promote terminal differentiation of PSCs through destabilization of abnormal methylation enzymes (MEs). The functionality of chemo-surveillance can be damaged under pathological conditions triggering the production of tumor necrotic factor (TNF) to cause cachexia symptoms. A manifestation of cachexia symptoms is the excessive urinary excretion of wound healing metabolites to affect terminal differentiation of PSCs to heal wound, allowing PSCs to evolve into cancer stem cells (CSCs), and then to progress to faster growing cancer cells (CCs) through activation of oncogenes and/or inactivation of suppressor genes. Since cancer is caused by wound unhealing. Thus, wound healing process offers the most appropriate modality of cancer therapy. CDA-2 is a preparation of wound healing metabolites purified from urine, which has superb therapeutic efficacy against myelodysplastic syndrome (MDS). MDS is a disease caused by the build up of CSCs unable to undergo terminal differentiation. Apparently, wound healing metabolites are the best medicine to eradicate CSCs. For the therapy of cancer, we propose to add another set of DI + DHI consisting of synthetic products to target CCs, since CCs are known to express high levels of salvage enzymes to support their faster growth. CDA formulations definitely can fulfill cancer moonshot. Perpetual replication of CCs is the most outstanding feature of cancer. Naturally, killing of CCs becomes the choice of cancer establishments to combat cancer in the past. This modality of cancer therapy has been drilled through as a presidential project, but failed to achieve the goal to win the war on cancer. The contribution to damage chemo-surveillance and the inability to eradicate CSCs are responsible for the failure to save cancer patients. A combination therapy with CDA formulations can eliminate such deficit to fulfill cancer moonshot.
References
Liau MC, Fruehauf JP. Winning formulas to fulfill cancer moonshot. Intl J Res Oncol 2022; 1(1): 1-5.
Liau MC, Fruehauf JP. It has been half a century since President Nixon declared war on cancer: destabilization of abnormal methylation enzymes has the blessing of the nature to win the war on cancer. Adv Complement Alt Med 2020; 6(1): 538-539.
Virchow R. Die Cellular pathologie in Ihrer Begrundung auf Physiologische und Pathologische Gewebelehve. Hirschwald 1858; 16: 440.
Dvorak HF. Tumors: wounds that do not heal. N Engl J Med 1986; 315(26): 1650-1659.
MacCarthy-Morrough L, Martin P. The hallmarks of cancer are also the hallmarks of wound healing. Science Signaling 2020; 13: 648.
Liau MC, Lin GW, Hurlbert RB. Partical purification and characterization of tumor and liver S-adenosylmethionine synthetases. Cancer Res 1977; 37(2): 427-435.
Liau MC, Chang CF, Giovanella BC. Demonstration of an altered S-adenosylmethionine synthetase in human malignant tumors xenografted into athymic nude mice. J Natl Cancer Inst 1980; 64(5): 1071-1075.
Liau MC, Zhuang P, Chiou GCY. Identification of the tumor factor of abnormal methylation enzymes as the catalytic subunit of telomerase. Clin Oncol Cancer Res 2010; 7(2): 86-96.
Liau MC, Szopa M, Burzynski B, Burzynski SR. Chemo-surveillance: a novel concept of the natural defense mechanism against cancer. Drug Exptl Clin Res 1989; 13(Suppl.1): 72-82.
Liau MC, Baker LL. The functionality of chemo-surveillance dictates the success of wound healing as well as cancer therapy. Novel Res Sci 2021; 7(2): 1-3.
Liau MC, Craig CL. Chemo-surveillance as a natural mechanism to ensure perfection of wound healing to avoid cancer evolution and to cure cancer. In: New Horizons in Medicine and Medical Research. 2022; Vol. 6, Chapter 3. Print ISBN:978-93-5547-607-4.
Liau MC, Lee SS, Burzynski SR. Hypomethylation of nucleic acids: a key to the induction of terminal differentiation. Intl J Exptl Clin Chemother. 1989; 2: 187-199.
Liau MC, Craig CL. On the mechanism of wound healing and the impact of wound on cancer evolution and cancer therapy. Intl Res J Oncol 2021; 5(3): 25-31.
Liau MC, Linda LL. Wound healing, evolution of cancer and war on cancer. Intl Res J Oncol 2021; 4(3): 13-
Liau MC, Craig CL. No scar as an indication of perfect wound healing, ugly scar as imperfect wound healing and cancer as failed wound healing. J Cancer Tumor Intl 2022; 12(1): 29-34.
Liau MC, Kim JH, Fruehauf JP. Destabilization of abnormal methylation enzymes: nature’s way to eradicate cancer stem cells. Online J Complement Alt Med DOI: 10.33552/OJCAM.2019.02.000546.
Hwa J, Martin K. Chapter 18: The eicosanoids: prostaglandins, thromboxanes, and related compounds. In: Katzung BG (ed) Basic and Clinical Pharmacology (14th ed) New York, NY: McGraw-Hill Education: 2017.
Ho ATV, Palla AR, Blake MR Yual ND, et al. Prostaglandin E2 is essential for efficacious skeletal muscle stem cell function, augmenting regeneration and strength. Proc Natl Acad Sci USA 2017; 114(26): 6675-
Liau MC, Kim JH, Fruehauf JP. Arachidonic acid and its metabolites as surveillance differentiation inducers to protect healthy people from becoming cancer patients. Clin Pharmacol Toxicol Res 2021; 4(1): 7-10.
Riciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 2011; 31(5): 986-1000.
Liau MC, Fruehauf PA, Zheng ZH, Fruehauf JP. Development of synthetic cell differentiation agent formulations for the prevention and therapy of cancer via targeting of cancer stem cells. Cancer Stud Ther 2019; 4(1): 1-15.
Liau MC, Craig CL. Wound healing metabolites to heal cancer and unhealed wounds. Intl Res J Oncol 2022; 6(3): 8-20.
Liau MC, Baker LL. The impact of COVID-19 pandemic on cancer patients. Intl Res J Oncol 2022; 6(4): 13-
Guo SA, DiPietro LA. Factors affecting wound healing. J Dent Res 2010; 89(3): 219-229.
Pollack SV. Wound healing: a review: III. Nutritional factors affecting wound healing. J Dermatol Surg Oncol 1979; 5(8): 615-619.
Itkin T, Rafi S. Leukemia cells “gas up” leaky bone marrow blood vessels. Cancer Cell 2017; 32(3): 276-
Passaro D, Di Tullo A, Abarrategi A, Rouault-Pierre K, et al. Increased vascular permeability in the bone marrow microenvironment contributes to disease progression and drug response in acute myeloid leukemia. Cancer Cell 2017; 32(3): 324-341.
Williamson PJ, Kruger AR, Reynolds PJ, Hamblin TJ, et al. Establishing the incidence of myelodysplastic syndromes. Br J Haematol 1987; 87(4): 743-745.
Boula A, Voulgarelis M, Gianouli S, Katrinakis G, et al. Effect of CA2 antitumor necrosis factor- antibody therapy on hematopoiesis of patients with myelodysplastic syndromes. Clin Cancer Res 2006; 12(10): 3099-3108.
Woll PS, Kjallquist U, Chowdhury O, Doolittle H, et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell 2014; 25(6): 794-808.
Maeck L, Haase D, Schoch C, Hiddemann W, et al. Genetic instability in myelodysplastic syndrome: detection of microsatellite and heterozygosity in bone marrow sample with karyotype alteration. Br J Haematol 2000; 109(4): 842-846.
Xie D, Hefmann KW, Mori N, Miller CW. Allotype analysis of the myelodysplastic syndrome. Leukemia 2001; 14(6): 805-810.
Kumamoto K, Ban S, Oda K, Tanaka H, et al. Chromosomal instability and radio sensitivity in myelodysplastic syndrome. Leukemia 2002; 16(11): 2253-2258.
Takada A, Goosby C, Yaseen NR. Nup98-HOXA9 induces long term proliferation and blocks differentiaition of primary human CD34+ hematopoietic cells. Cancer Res 2006; 66(13): 6628-6637.
Liau MC, Kim JH, Fruehauf JP. Destabilization of abnormal methylation enzymes to combat cancer: the nature’s choice to win the war on cancer. Lambert Academic Publishing 2020; 978-620-2-66889-7.
Prassana P, ShackS, Wilson VL, Samid D. Phenyacetate in chemoprevention of 5-aza-2’-deoxycytidineinduced carcinogenesis. Clin Cancer Res 1995; 1(18): 865-871.
Gaudet F, Hodgson JG, Eden A, Jaackon-Grudy L, et al. Induction of tumors in mice by genomic hypomethylation. Science 2003; 300(5618): 489-492.
Palii SS, van Emburgh BO, Sankpal UT, Brown KD, et al. DNA methylation inhibitor 5-aza-2’-deoxycitidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferase1 and 3B. Mol Cell Biol 2008; 28(2): 752-771.
Yang Q, Wu F, Wang F, Cai K, et al. Impact of DNA methyltransferase inhibitor 5-azacytidine on cardiac development of zebrafish in vivo and cardionyocyte proliferation, apoptosis, and the hemostasis of gene expression in vitro. J Cell Biochem 2019; 120(10): 17459-17471.
Liau MC. Pharmacerutical composition inducing cancer cell differentiation and the use for the treatment and prevention of cancer thereof. US Patent 2007; 7232578 B2.
Kampalath BN, Liau MC, Burzynski B, Burzynski SR. Protective effect of Antineoplaston A10 in hepatocarcinogenesis induced by aflatoxin B1. Intl J Tissue React 1990; 12(Suppl): 43-50.
Liau MC, Kim JH, Fruehauf JP. In pursuance of differentiation inducers to combat cancer via targeting of abnormal methylation enzymes. J Cancer Tumor Intl 2020; 10(2): 39-47.
Bacanelli AC, Turner FB, Xie LY, Taylor SM, et al. A mouse gene that coordinate epigenetic controls and transcriptional interference to achieve tissue specific expression. Mol Cell Biol 2008; 28(2): 836-848.
Liau MC, Hunt ME, Hurlbert RB. Role of ribosomal RNA methylases in the regulation of ribosome production. Biochemistry 1976: 15(14): 3158-3164.
Bernstein KA, Bleichert F, Bean JM, Cross FR, et al. Ribosome biogenesis is sensed at the start cell cycle check point. Mol Biol Cell 2007; 18(3): 953-964.
Justilien Y, Ali SA, Jamieson L, Yin N, et al. ECT2-dependent rRNA synthesis is required for KRAS-TRP53-driven lung adenocarcinoma. Cancer Cell 2017; 31(2): 256-269.
Liau MC, Chang CF, Saunder GF, Tsai YH. S-adenosyhomocysteine hydrolases as the primary target enzymes in androgen regulation of methylation complexes. Arch Biochem Biophys 1981; 208(1): 261-272.
Liau MC. Abnormal methylation enzymes: a selective molecular target for differentiation therapy of cancer. Chin Pharm J 2004; 56(2): 57-67.
Prudova A, Bauman Z, Braun A, Vitvitsky V, et al. S-Adenosylmethionine stabilizes cystathionine -synthase and modulates redox capacity. Proc Natl Acad Sci USA 2006; 103(17): 6489-6494.
Chiba P, Wallner C, Kaizer E. S-Adenosylmethionine metabolism in HL-60 cells: effect of cell cycle and differentiation. Biochim Biophys Acta 1988; 971(1): 38-45.
Liau MC, Baker LL. Abnormal methylation enzymes as the bullseye of targeted cancer therapy. Nov Res Sci 2021; 7(6): 1-3.
Liau MC, Baker LL. Cancer patients’ lives matter. Adv Complement Alt Med 2021; 6(5): 638-640.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Ming C. Liau, Christine L. Craig, Linda L. Baker
This work is licensed under a Creative Commons Attribution 4.0 International License.
